| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-12-12 | Defymed (France) Semma Therapeutics (USA - MA) | MAILPAN® bio-artificial pancreas in combination with stem-cell derived differentiated insulin-secreting cells | type 1 diabetes | development | Metabolic diseases | Development agreement |
| 2016-12-09 | AstraZeneca (UK) Eli Lilly (USA - IN) | AZD3293, MEDI1814 | Alzheimer’s disease | development - commercialisation | Neurodegenerative diseases | Development agreement |
| 2016-12-09 | Enterome Bioscience (France) | nomination |
Nomination | |||
| 2016-12-08 | Cymabay Therapeutics (USA - CA) | nomination |
Rare diseases - Hepatic diseases - Liver diseases | Nomination | ||
| 2016-12-08 | Kiadis Pharma (The Netherlands) | nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2016-12-08 | Kiadis Pharma (The Netherlands) | nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2016-12-07 | Polyphor (Switzerland) Novartis (Switzerland) | PEM (Protein Epitope Mimetic) drug discovery technology | R&D, research | Technology - Services | Milestone | |
| 2016-12-07 | Neurimmune (Switzerland) TVM Capital Life Science (Germany) AL-S Pharma (Switzerland) | establishment of a new company in the EU |
Rare diseases - Genetic diseases - Neurodegenerative diseases | Establishment of a new subsidiary in the EU | ||
| 2016-12-07 | Tmunity Therapeutics (USA - PA) | president, chief executive officer | nomination | Cancer - Oncology | Nomination | |
| 2016-12-07 | Adverum Biotechnologies (USA - CA) Synpromics (UK) | promoters for the treatment of eye diseases | research - development - R&D | Ophtalmological diseases - Genetic diseases - Rare diseases | Development agreement | |
| 2016-12-06 | Shire (UK - USA) | biologics manufacturing campus at Piercetown, County Meath (Ireland) | construction of a production plant |
Rare diseases | Construction of a production plant | |
| 2016-12-06 | Anthera Pharmaceuticals (USA - CA) | nomination |
Nomination | |||
| 2016-12-05 | OncoMed Pharmaceuticals (USA - CA) | resignation |
Cancer - Oncology | Resignation | ||
| 2016-12-05 | Spark Therapeutics (USA - PA) Selecta Biosciences (USA - MA) | Synthetic Vaccine Particles (SVP™) platform technology | hemophilia A and up to four additional undisclosed genetic targets | licensing |
Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2016-12-05 | Spark Therapeutics (USA - PA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-12-05 | F2G (UK) | Infectious diseases | Nomination | |||
| 2016-12-05 | Aegerion Pharmaceuticals (USA - MA), subsidiary of Novelion Therapeutics (Canada) Amryt Pharma (UK) | Lojuxta® (lomitapide) | homozygous familial hypercholesterolemia (HoFH) | licensing |
Rare diseases - Genetic diseases - Cardiovascular diseases | Licensing agreement |
| 2016-12-05 | Acticor Biotech (France) Merck KGaA (Germany) | Provantage® End-to-End services | services contract |
Technology - Services | Services contract | |
| 2016-12-05 | Sanofi (France) JHL Biotech (Taiwan) | biological therapeutics including a biosimilar version of Mabthera®/Rituxan® - rituximab | collaboration development commercialisation |
Collaboration agreement | ||
| 2016-12-05 | ViiV Healthcare (UK - USA) | nomination - resignation | Infectious diseases | Nomination |
